Introduction
In the egocentric view of a stem cell biologist, the main source of all ailments in the industrialized world is largely a matter of stem cell dysfunction. With time and age, our stem cells accumulate more and more mutations, losing self-renewal and plasticity. Ultimately, regeneration of the whole tissue or organ is sluggish and compromised. The cumulative acquisition of mutations in the stem cell pool throughout our life can eventually transform stem cells and their clonal descendants and eventually generate an invasive cancer. With this view in mind, understanding the biology of stem cells is a priority for regenerative medicine and cancer researchers.
The origin of stem cells and their involvement in tissue regeneration and cancer can be traced to the evolution of multicellular organisms and the development of specialized cells and tissues. Compared to single-celled organisms, multicellular tissues face not only the problem of self-renewal for tissue regeneration, but also the problem of cell differentiation and 'cell-to-cell' interaction. Consequently, the cooperation necessary among single cells causes organized tissues to lose autonomous growth characteristics. But this loss can eventually be regained by accident-with one major consequence: the development of cancer. How cells gained autonomous growth has been at the center of cancer biology for several decades of research. Interestingly, the cellular origin of the cancer cells has not been the focus of many researchers until recently. The currently accepted model of cancer stem cells has provided some momentum in cancer research, since, as we will discuss in this review, evidence has emerged for a stem cell contribution in tumor biology. But not surprisingly, many questions remain unanswered. The primary issue is our lack of knowledge concerning the nature of normal stem cells and the signals which control stem cells and tumor cells in general. In this review, we summarize the current concepts of stem cells and cancer stem cells, draw attention to the current understanding of genetic instability in cancer and describe an updated model of cancer stem cells in the context of stem cells and genetic instability. Further, we discuss the implications of this new model for cancer biology and anticancer therapies.
The concept of stem cells
In somatic tissues, cells are organized into a hierarchy, with stem cells residing at the beginning of the cellular pathway leading to a variety of mature cells. Stem cells are undifferentiated cells found among the more differentiated cells grouped together to form tissues. The next level of organization, the organ, contains several types of tissue functioning together for a common purpose. For this reason, different stem cells representing different tissues can be found in a single organ, making the identification and characterization of organ-specific stem cells challenging, and the regeneration of organs and body parts complex.
The rigorous definition of a stem cell requires that it possess at least two distinct properties, self-renewal and multilineage commitment. Stem cells self-renew by dividing and giving rise to a daughter cell retaining the same biological properties as the parent cell. Stem cells can also differentiate into multiple lineages, producing a wide range of specialized cell types. Such lineage commitment varies from stem cell to stem cell depending on the tissues they originated. Stem cells are not well characterized for many somatic tissues. Very few assays have been developed which demonstrate the distinctive properties of selfrenewal and lineage commitment at the clonal level.
Most of our current knowledge of stem cell biology comes from experiments in the normal hematopoietic system (blood) where the identification of hematopoietic stem cells (HSC) has led to the prospective identification of the different cells responsible for the hematopoietic lineage. [1] [2] [3] In the vertebrate, the hematopoietic system produces a minimum of eight distinct lineages of blood cells (see review by Kondo et al. 4 ). Three cell types, stem cells, progenitor cells and mature cells, constitute the cellular pathway which contributes to the continuous production of blood cells throughout adult life. The stem cells are the only cells, which have the properties of selfrenewal and multilineage differentiation. The progenitor cells have lost the ability to self-renew but have, in general, a transient but high-proliferative capacity. Progenitor cells will eventually differentiate into mature cells which have a finite half-life and can induce apoptotic pathways to allow replacement by incoming, freshly differentiated, mature cells. Based on the properties of HSC, the isolation of tissue-derived stem cells from solid organ was anticipated. So far, the best identified stem cells for a solid organ are the neural stem cells (NSC) (see, for example, references [5] [6] [7] [8] ).
Broadly speaking, NSC resemble HSC by sharing the stem cell fundamental properties of self-renewal and multilineage commitment, generating neurons, astrocytes and oligodendrocytes. Both HSC and NSC populations provide the foundation for a better understanding of stem cell biology. But attempts to define a genetic signature of stemness by comparing these adult stem cells at the molecular level have been disappointing. 9 Although these different tissue-derived stem cells share the fundamental properties of self-renewal and the potential to differentiate into diverse mature cells, they also differ substantially in their functions from one another. Thus, some properties defined for stem cells of one tissue are not always shared with the stem cells from a different tissue. This observation must be considered as we discuss the theory of cancer stem cells.
Stem cell properties of cancer
Cancer cells share striking properties with stem cells. Do stem cells simply turn into cancerous stem cells? We briefly review some of the intrinsic and extrinsic stem cell properties found in cancer.
Cancer and self-renewal
Perhaps the most important and obvious intrinsic stem cell property reported for cancer cells is self-renewal (see review by Reya et al. 10 ). Cancer cells constitute a reservoir of self-sustaining tumor cells with the extraordinary ability to self-renew and maintain the tumor. Pathways which regulate oncogenesis, such as Notch, Wnt and Hedgehog, have been shown to be involved in stem cell self-renewal. 10 Another example is the polycomb family of the proto-oncogene Bmi-1, crucial to the self-renewal potential of many adult stem cells, 11 it is also necessary for the proliferation of cancer cells. 12, 13 Networks of proto-oncogenes and tumor suppressor genes which regulate stem cell homeostasis can cause neoplasia and, eventually, cancer when imbalances within such a network occur. 14, 15 Normally, stem cell renewal and expansion is essential during tissue development and to activate the repair or regeneration of tissue and organs injured or under stress. However, this expansion may also confer an inherent risk of cancer. Promoting the self-renewal machinery in stem cells may also permit the occurrence of secondary events leading to cancer. 15 An interesting example is a report of the presence of chromosomal abnormalities promoting self-renewal in fly neuroblasts. 16 By inserting a mutation in various genes which control asymmetric cell division in Drosophila melanogaster larva neuroblasts, the functional loss of any of the genes which control the fate of a stem cell's daughter cells resulted in uncontrolled self-renewal which destabilized stem cell homeostasis and led to cancer. The defect was traced to a deficient centrosome. Since centrosomes form the poles of the mitotic spindles, this abnormality led to errors in chromosome segregation and aneuploidy. 16 Although any parallel to human stem cells and cancer remains purely speculative, centrosome abnormalities are a frequent finding in human neoplasms and may drive cells toward genomic instability. 17, 18 On the other hand, an alternative possibility for secondary events such as centrosome alteration may simply reflect the loss of genomic stability by other mechanisms. 19 
Cancer and stem cell niches
Stem cell homeostasis is dependent on the interaction of stem cells with stromal cells which comprise a special environment called a 'niche'. By definition, stem cell niches provide an extrinsic environment promoting stem cell maintenance and survival in an undifferentiated state via self-renewal. The stem cell niche is best documented in the studies of the Drosophila germ cell niche, including cap cells in Drosophila ovary and hub cells in Drosophila testis, where both intrinsic and extrinsic signals have been identified (see review by Fuller and Spradling 20 ) . To maintain tissue homeostasis, the number of stem cells needed in each tissue must remain steady and the replenishment following a sudden need for progenitor and mature cells has to be managed without a long-term expansion of the stem cell pool. The stem cell niche is composed of a microenvironment of somatic support cells which are a physical anchorage for the stem cells. These somatic support cells provide extrinsic signal transduction pathways as well as direct the orientation of stem cell mitotic spindles controlling asymmetric division and balancing self-renewal versus differentiation. 21 Because of this tight control of stem cells, the origin of cancerous stem cells may arise by two independent mechanisms, intrinsic mutation which renders proliferation and expansion of stem cells Cancer stem cells with genetic instability E Lagasse independent from the homeostatic control of the niche, or an extrinsic mutation of stem cells via deregulation of the niche by mutation of the signals controlling proliferation and/or expansion. Possibly independent of stem cells niches, an analogous system of specialized tissue microenvironment cells has been described during carcinogenesis. The 'tumor cell niche', principally composed of mesenchymal tissue, has been shown to support survival and self-renewal of tumor cells and accumulating evidence has pointed to tumor stroma influence in tumor development. Genetic studies strongly support the concept of stroma-tumor cell interaction. 22, 23 In the development and progression of neoplasia, such as mammary carcinoma, concurrent and independent genetic alterations in stromal and epithelial cells were detected. 24 In this study, genetic alterations in stromal cells have been suggested to precede genotypic changes in the epithelial cells. Although the tumor cell niche plays a critical role in epithelial tumorigenesis, the signals mediating these effects are poorly understood.
Cancer, clonality and heterogeneity
Another remarkable stem cell property of cancer is the clonal origin of most tumors. Similar to organogenesis, which is orchestrated at the single cell level from tissuederived stem cells, it is generally accepted that the natural history of a cancer is determined by the clonal expansion of a single progenitor cell transformed at the start of the oncogenic process. [25] [26] [27] In human leukemia, clonality could be assessed by molecular markers of clonality such as specific leukemia associated translocation products like Bcr-Abl 28, 29 or alternatively by analysis of T-cell receptor rearrangement over a prolonged time span. 30 In solid tumors, clonal expansion is supported by the identification of shared genetic traits inherited from a common ancestor, even if additional genomic alterations have arisen in subsequent metastases, 31 usually due to chromosomal instability. [32] [33] [34] Despite the fact that cancer arises from a single tumor cell, early experiments by Hamburger and Salmon 35, 36 found that only one in a few thousand tumor cells were capable of forming a colony in soft agar, an alternate assay for determining stem cell frequency. Tumor cell heterogeneity demonstrated in vitro can also be confirmed in vivo, in an assay establishing tumorigenicity. 37, 38 Heterogeneity is a common feature in tumor cells. But tumor cells express heterogeneity in several ways other than their proliferative abilities. Intratumoral heterogeneity of DNA content and gene expression in part raises the possibility of the presence of different cellular populations of tumor cells. 39 The clonal origin of cancers along with the presence of a heterogeneous population of cancer cells after tumor expansion suggests that cancer may undergo a process similar to organogenesis with stem cell selfrenewal and cell differentiation. Two theories and models have been proposed, and opposed, to explain the heterogeneity in tumor cells. 10, 40 The stochastic model is governed by the probability of stochastic events in the tumor cell population, either genetic and/or epigenetic events, which could potentially transform any cell to a tumor-initiating cell. By contrast, the hierarchy model predicts that tumor cells are functionally heterogeneous and only a limited number of tumor cells are capable of initiating tumor, that is, the cancer stem cells. Both models predict that only a fraction of tumor cells are capable of initiating cancer, yet the underlying biological mechanisms are fundamentally different.
Hierarchy model, cancer stem cells and cancerous stem cells
The possible role for stem cells in cancer etiology is not a recent concept. [41] [42] [43] Conheim, with the embryonic 'cell rest' theory, was one of the first to propose that tumors arise from embryonic (stem-like) cells which persist in the tissues and fail to mature. 44 Similar to normal stem cells, most of our understanding of cancer stem cells comes from the hematopoietic system. Using leukemia as a model, the first quantitative assay for the frequency of the malignant cancer initiating cells was demonstrated by the transplantation of a single leukemic cell transmitting the systemic disease in an animal model. 27 Later, the two-stage experimental model of skin cancer suggested a two-step process in solid tumor development, tumor initiation and tumor promotion, by exposing animal models to carcinogenic or mutagenic agents. 45 Tumor initiation is thought to involve conversion of rare epidermal stem cells into latent neoplastic cells, whereas tumor promotion, possibly at a much later stage, elicits expression of the neoplastic change (see review by Morris 46 ). This experimental model makes a convincing case for the involvement of stem cells in the tumorigenic response. Despite a possible interval of a few days to a year between initiation and promotion of skin cancer, the tumorigenic response remains similar. This observation strongly suggests that only the 'initiated cells' and remaining target cells are the long lasting and slowdividing epithelial stem cells, since all the other skin cells present during the exposure to the carcinogenic agent are no longer present during tumor promotion. However, it is only very recently that the identification and characterization of the first cancer stem cells was proposed in myeloid leukemia. 47 Here, the investigators demonstrated the hierarchy model for leukemia with only a fraction of the leukemic cells showing stem cell attributes with the capability of initiating the disease in recipient mice. Other recent studies have shown the hierarchy stem cell model can also be applied to solid tumors. [48] [49] [50] [51] [52] In these studies, biologically different and relatively rare populations of tumor-initiating cells have been described in breast, brain and colon cancer. These recent results support the concept that only a subset of cancer cells within the tumors may self-renew, initiate and drive the tumor growth. Given these features, at least two scenarios have been proposed for the origin of tumor initiating cells. In the first, neoplastic transformations may arise in stem cells and their expansion results in cancerous stem cells. 47 In the second, neoplastic transformations may activate self-renewing genes in transit amplifying progenitor cells, 53, 54 allowing further mutations to accumulate in what have now become cancer stem cells. Thus, different target cells may be mutated during normal developmental pathways and would be present at the formation of cancer stem cells, driving tumor growth and tumor heterogeneity and even metastases. Because the identification of tissue-derived stem cells has not been clearly defined for most of the various epithelial tissues, the relationship of these newly 
Stochastic mutation, genetic instability and cancer
The tumorigenic process proceeds by the accumulation of inherited and randomly acquired somatic mutations. 34, 55 In addition, many cancers can also acquire epigenetic changes, which may have a profound effect at the level of gene expression. 56 For most cancers, numerous somatic changes will accumulate stochastically at the nucleotide, gene and/or chromosome level. However, because the high number of mutations necessary to transform a normal cell into a cancer cell may not be achievable with a normal mutation rate, it has also been proposed that an unstable genome would be necessary for such a transformation. 29 These findings have led to the controversial issue in cancer biology that genomic instability, and in particular, chromosome instability (CIN), is at the origin of cancer. 57, 58 Genomic instability is a common finding in the later stages of cancer, when tumor cells invade distant sites during the metastatic process. However, as discussed previously, two radically different mechanisms have been proposed for the presence of genetic instability in cancer cells, the causative process responsible for cancer development and its metastatic evolution, or, the consequence and product of the malignant process. Our knowledge of various forms of genetic instability in many kinds of cancer is limited. Many genetic mechanisms have been proposed for CIN. In yeast, 130 genes have been identified to cause a CIN phenotype. 59 This extensive catalog of genome instability indicates the complexity of the genes responsible for CIN. Along with mutational changes in nucleotides, epigenetic events could certainly have an important role. 60 In this perspective, the most appropriate model, and best study, is the initiation of tumorigenesis in colon cancer. The colon is made up of more than 10 million crypts. Each crypt contains one stem cell at the base with many continually differentiating cells traveling rapidly to the top, where mature cells undergo apoptosis. The rapid turnover of this tissue is compensated by rapid cell division, which presents a risk for mutational events and cancer. The inactivation of the adenomatous polyposis coli (APC) tumor-suppressor gene of the Wnt signaling pathway is considered the first step in the initiation of sporadic colon cancer. About 85% of all sporadic colon cancers have APC mutation and most of the remaining mutations are located downstream of APC, in the b-catenin gene. With APC and b-catenin mutations, cell proliferation increases and the crypt becomes dysplastic with an increase in the number of abnormal colon cells. Further mutations, KRAS, TGF-b, p53 and other pathways will induce the progression of large polyps into cancerous lesions. 57, 61 Clonal selection of tumor cells by stochastic and advantageous mutation creates a progression in the tumorigenic process until genetic instability develops into a driving force. 33 About 85% of sporadic colorectal cancers are aneuploid, that is, contain an abnormal chromosome content thought to be a consequence of CIN. Although aneuploidy is an observation of the static content of abnormal chromosomes in cells, experimental evidence has shown that aneuploidy develops in cancer because of CIN, with an accelerated rate of chromosomal gains or losses. 55 Another genomic instability mechanism, microsatellite instability (MIN), was found in repetitive DNA sequences and represents the remaining 15% of colorectal cancer. MIN is characterized by a mismatch repair deficiency, secondary to the loss of genes such as MLH1 or MSH2. 62 Cancer cells with MIN have a higher mutation rate at the nucleotide level (two to three orders of magnitude higher than normal cells) with a diploid to near diploid chromosomal content.
Cancer stem cells, genomic instability and clinical implications
Given the unique property of stem cell self-renewal, it is not surprising that they are the most appropriate cells to accumulate stochastic mutations. As stem cells divide over the course of many years, acquired mutations accumulate in the stem cell pool. Specific mutations with a characteristic sequence provide a growth advantage to the mutated stem cells. Dysplasia and early adenoma followed by genomic instability supply the necessary mutation rate in the stem cell population to initiate cancer and its metastases. Little experimental evidence supports this model for solid tumor formation. 63 But recent progress in targeting leukemic cells in chronic myeloid leukemia (CML) has given an insight into a cancer with stem cell-like properties and the possible consequence of genomic instability in cancer stem cells. 64, 65 CML is a blood disorder driven by the mutant kinase fusion protein Bcr-Abl. CML was one the first human cancers to be associated with an abnormal chromosome, the Philadelphia chromosome, involving the translocation of chromosome 9 and 11. Furthermore, CML stem cells have been well characterized. [66] [67] [68] [69] Extensive research of drugs for an effective targeted molecular therapy against the mutant kinase fusion BcrAbl resulted in the discovery of a kinase inhibitor, imatinib mesylate or Gleevec, which yielded an effective treatment for CML patients. 70, 71 However, despite the remarkable clinical response achieved with imatinib, many patients had residual disease. Primitive and quiescent CML stem cells were insensitive to the treatment. 72 Only the progeny of cancer stem cells were affected by the treatment since CML recurred as soon as the therapy was discontinued. 73 Data suggested that even sequential treatment with multiple tyrosine kinase inhibitors still failed to eradicate CML stem cells. 74 Because CML progression is characterized by chromosomal abnormality, it has been proposed that genomic instability is the amplifier of the genetically unstable phenotype observed. 75 
Genetic instability, a Darwinian selection for tumors
The fundamental process of evolution is based on the importance of twin driving forces: mutation and natural selection. As with evolution, the process of a malignant phenotype in cancer is based on somatic mutations and Cancer stem cells with genetic instability E Lagasse selection, with genomic instability undoubtedly increasing tumor cell survival fitness.
A well-known example of natural selection is the development of antibiotic resistance in microorganisms. Since the discovery of penicillin in 1928 by Alexander Fleming, antibiotics have been used to fight bacterial infections. Natural populations of bacteria are known to contain considerable variation in their genetic material, primarily due to mutations accumulated during the rapid growth rate. When exposed to a short course of antibiotics, most bacteria die, but some bacteria survive due to mutations, which make them slightly less susceptible to the drug. This selective elimination of the maladapted individuals and survival of the fittest is called natural selection. The surviving bacteria reproduce, again with variation in their genetic material, and turn out a new generation with increased resistance to the antibiotic. After enough time and repeated exposure to the same antibiotic, a population of antibiotic-resistant bacteria emerges.
This simple concept can be applied to cancer stem cells (See Figure 1) . The hypothesis of cancer stem cells is based on the fact that, in most recurrent cancers, a small reservoir of drug-resistant tumor cells is responsible for the relapse of the cancer after chemotherapy-induced remission. Similar to the natural selection occurring in bacteria after short-term antibiotic exposure, cancer stem cells may contain considerable variation in genetic materials due to genomic instability. When exposed to chemotherapy, some of the cancer stem cells may harbor mutations which make them slightly less susceptible to the chemotherapeutic drug. After repeated exposure to chemotherapy, resistance to most nonlethal chemotherapeutic drug concentrations will emerge. Furthermore, selection and adaptation with new mutations is a wellknown clinical phenomenon reported in tumor cells. 76 
Challenges and future directions
Many challenges remain to the researcher. These include the clinical demonstration that cancer stem cells can be used as a prognostic indicator of disease progression and proof that the eradication of cancer stem cells from a patient's tumor is therapeutic. For now, the identification of cancer stem cells in every cancer and the development of targeted therapy for cancer stem cells is a necessary goal. The isolation and characterization of normal stem cells is another priority, as most of the new drugs targeting cancer stem cells must be without consequences for normal stem cells. A better understanding of both cancer stem cells and normal stem cells will not Cancer stem cells with genetic instability E Lagasse only be valuable for cancer and cancer biology but also for cell therapy and regenerative medicine. Obviously, another important issue to investigate is genomic instability and how it affects resistance to existing and possible future chemotherapeutic agents. Further, elucidation of the genetic basis of genomic instability will hopefully provide us with a mechanistic understanding of this process.
